DENTSPLY SIRONA Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data DENTSPLY SIRONA Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	3,745	3,993	3,986	4,022	3,339	4,231	3,922	3,965	3,793	3,680
Cost of revenue	1,744	1,805	1,918	1,858	1,683	1,884	1,795	1,879	1,835	1,840
Gross profit	2,001	2,189	2,068	2,164	1,656	2,347	2,127	2,086	1,958	1,840
Research and development	129	152	161	143	123	171	174	184	165	150
Selling, general and administrative	1,523	1,675	1,719	1,587	1,302	1,551	1,589	1,613	1,605	1,438
Operating income	455	-1,562	-958	353	-3	608	-937	-85	-879	-422
Interest expense	35.9	38.3	37	30	48	61	65	81	69	88
Interest income	2	2.4	2	2	1
Other non-operating income	20.1	-5.3	35	12	-1	-2	-53	-9	12	24
Pre-tax income	441	-1,604	-958	338	-50	545	-1,055	-175	-936	-486
Income tax	9.5	-53.2	53	82	23	134	-105	-43	-26	112
Net income to minority interests	1.5	-0.3	0	0	0	0	0	0	0	0
Net income	430	-1,550	-1,011	256	-73	411	-950	-132	-910	-598
EBITDA	726	-1,246	-627	676	331	955	-609	258	-530	-70
EPS, basic	1.97	-6.76	-4.51	1.15	-0.33	1.88	-4.41	-0.62	-4.48	-3.00
EPS, diluted	1.94	-6.76	-4.51	1.14	-0.33	1.87	-4.41	-0.62	-4.48	-3.00
Shares, basic (weighted)	218	229	224	223	219	218	216	212	203	199
Shares, diluted (weighted)	222	229	224	224	219	220	216	212	203	199
Dividend per share	0.31	0.35	0.35	0.38	0.40	0.43	0.50	0.56	0.64	0.64

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	384	321	310	405	438	339	365	334	272	326
Receivables	636	746	702	782	667	750	632	695	556	688
Inventory	517	623	599	562	476	515	627	624	564	642
Other current assets	207	313	123	84	67	84	88	113	153	150
Total current assets	1,744	2,003	1,888	2,000	1,798	1,852	1,893	1,973	1,746	2,023
Property, plant and equipment	800	876	871	802	791	773	761	800	766	861
Lease right-of-use assets				159	176	198	200	178	136	139
Goodwill	5,952	4,539	3,431	3,397	3,986	3,976	2,688	2,438	1,597	1,148
Intangible assets	2,958	2,801	2,420	2,176	2,504	2,319	1,903	1,705	1,207	974
Other non-current assets	103	156	76.8	69	95	121	198	276	301	284
Total assets	11,556	10,375	8,687	8,603	9,350	9,239	7,643	7,370	5,753	5,429
Accounts payable	223	284	284	308	302	262	279	305	241	300
Accrued liabilities	463	586	579	629	712	760	727	749	754	700
Deferred revenue			29.3	29	53	68	84	91	95	74
Short-term debt	21.1	30.1	92.4	2	299	182	118	322	549	313
Total current liabilities	768	955	1,013	995	1,372	1,261	1,170	1,425	1,589	1,343
Long-term debt	1,511	1,612	1,565	1,433	1,978	1,913	1,826	1,796	1,586	2,015
Lease liabilities				120	130	149	149	125	91	93
Other non-current liabilities	400	463	423	480	554	528	399	502	415	544
Total liabilities	3,430	3,747	3,554	3,508	4,415	4,242	3,831	4,076	3,810	4,089
Total debt	1,528	1,626	1,580	1,438	2,284	1,922	1,871	1,909	1,748	2,276
Paid-in capital	6,517	6,544	6,522	6,587	6,604	6,606	6,629	6,643	6,640	6,644
Retained earnings	3,948	2,316	1,226	1,404	1,198	1,514	456	205	-835	-1,564
Treasury stock	-1,647	-1,955	-2,151	-2,301	-2,409	-2,535	-2,649	-2,922	-3,136	-3,105
Other comprehensive income	-706	-291	-479	-600	-464	-592	-628	-636	-730	-639
Shareholders' equity	8,114	6,616	5,121	5,093	4,932	4,996	3,811	3,293	1,942	1,339
Minority interests	11.6	11.6	11.9	2	3	1	1	1	1	1
Total equity	8,126	6,628	5,083	5,048	4,935	4,997	3,812	3,294	1,943	1,340
Total liabilities and equity	11,556	10,375	8,687	8,603	9,350	9,239	7,643	7,370	5,753	5,429
Shares outstanding	230	227	223	221	219	217	215	207	199	200

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	431	-1,550	-1,011	256	-73	411	-950	-132	-910	-598
Depreciation and amortization	272	316	331	323	334	347	328	343	349	352
Stock-based compensation	41.3	48	21	66	47	48	59	46	39	33
Deferred income tax	-110	-144	-62	-40	-62	-25	-228	-130	-136	30
Change in inventory	65.4	-62.9	-20	11	123	-64	-141	6	17	-17
Change in payables	7.2	44.2	7	27	-28	-49	30	14	-30	11
Cash from operations	563	602	500	639	649	657	517	377	461	235
Capital expenditures	-125	-144	-183	-123	-87	-142	-149	-149	-180	-131
Acquisitions	-342	-146	-130	-3	-1,078	-248	0
Purchases of investments	-6.8	-2.5	-4	0	0
Sales and maturities of investments	0	0	54	0	0
Cash from investing	60	-286	-253	-69	-1,106	-358	-138	-89	-197	-132
Debt issued						16	6	0	1	553
Debt repaid	-878	-16.7	-9	-251	-701	-297	-2	-7	-88	-147
Stock issued	41	82.3	28	109	11	51	6	0	0
Share buybacks	-814	-401	-250	-260	-140	-200	-150	-300	-250	0
Dividends paid	-64.6	-78.3	-79	-81	-88	-92	-104	-116	-126	-128
Cash from financing	-526	-401	-250	-472	476	-379	-329	-307	-302	-80
Exchange rate effect	2.1	22	-8	-3	14	-19	-24	-12	-24	31
Net change in cash	99.3	-63.3	-11	95	33	-99	26	-31	-62	54
Free cash flow	438	458	317	516	562	515	368	228	281	104
Interest paid	36.7	37	35	30	45	64	70	97	91	66
Income taxes paid	112	123	105	112	82	148	122	177	74	71

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $9.40 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	49.5%	Gross profit / revenue.
Operating margin	-8.5%	Operating income / revenue.
EBITDA margin	1.1%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-9.5%	Pre-tax income / revenue.
Net margin	-15.0%	Net income / revenue.
FCF margin	3.9%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	8.8%	Cash from operations / revenue.
Return on equity (ROE)	-40.4%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-10.5%	Net income / average total assets.
Return on invested capital (ROIC)	-7.9%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	4.6%	Research and development expense / revenue.
SG&A / revenue	39.9%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	0.9%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	4.8%	Capital expenditures / revenue.
D&A / revenue	9.6%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-3.0%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-2.1%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	2.0%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-6.0%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-4.7%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	2.1%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-49.0%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	-23.1%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-18.4%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	-63.0%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	-34.4%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	-28.6%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Dividend per share growth, 1y	0.0%	Dividend per share vs the same period a year earlier. Only from a positive base.
Dividend per share CAGR, 3y	8.6%	Compound annual growth of dividend per share over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Dividend per share CAGR, 5y	9.9%	Compound annual growth of dividend per share over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-31.1%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-29.4%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	-23.0%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-5.6%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-10.8%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-10.3%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-1.9%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-2.6%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-1.9%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.63x	Current assets / current liabilities.
Quick ratio	0.72x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.20x	(Cash + short-term investments) / current liabilities.
Debt / equity	1.48x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	38.4%	Total debt / total assets.
Liabilities / assets	74.0%	Total liabilities / total assets.
Net debt	$1.76B	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	45.1x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Interest coverage	-3.41x	Operating income / interest expense.
Working capital	$743.0M	Current assets - current liabilities.
Goodwill and intangibles / assets	38.6%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$657.0M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.70x	Revenue / average total assets.
Fixed asset turnover	4.31x	Revenue / average property, plant and equipment.
Inventory turnover	2.77x	Cost of revenue / average inventory.
Days inventory	132 days	365 x average inventory / cost of revenue.
Receivables turnover	5.88x	Revenue / average receivables.
Days sales outstanding	62 days	365 x average receivables / revenue.
Days payables	52 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	143 days	Days inventory + days sales outstanding - days payables.
Capex / operating cash flow	55.2%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$2.72	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$18.17	Revenue / diluted weighted shares.
FCF per share	$0.71	Free cash flow / diluted weighted shares.
Operating cash flow per share	$1.59	Cash from operations / diluted weighted shares.
Book value per share	$6.78	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$3.30	Tangible book value / shares outstanding.
Cash per share	$1.20	(Cash + short-term investments) / shares outstanding.
Dividends / FCF	67.1%	Dividends paid / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$1.87B	Share price x shares outstanding.
Enterprise value	$3.63B	Market cap + total debt - cash - short-term investments.
P/S	0.51x	Market cap / revenue.
P/B	1.39x	Market cap / shareholders' equity. Only when equity is positive.
P/FCF	13.1x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	5.87x	Market cap / cash from operations, when positive.
EV/Sales	1.00x	Enterprise value / revenue.
EV/EBITDA	93.1x	Enterprise value / EBITDA, when both are positive.
EV/FCF	25.4x	Enterprise value / free cash flow, when both are positive.
FCF yield	7.6%	Free cash flow / market cap.
Earnings yield	-29.1%	Net income / market cap (the inverse of P/E).
Dividend yield	5.1%	Dividends paid over the period / market cap.
Shareholder yield	5.1%	(Dividends paid + share buybacks) / market cap.

What was DENTSPLY SIRONA Inc.'s revenue in fiscal 2025?

DENTSPLY SIRONA Inc. reported revenue of $3.68B for fiscal 2025, 3% lower than the year before.

Was DENTSPLY SIRONA Inc. profitable in fiscal 2025?

No. It reported a net loss of $598.0M.

How much free cash flow did DENTSPLY SIRONA Inc. generate in fiscal 2025?

Cash from operations of $235.0M minus capital expenditures of $131.0M left free cash flow of $104.0M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to DENTSPLY SIRONA Inc.